Summary

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030F. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.
Key Market Drivers
Escalating Diabetes Epidemic
The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.
Key Market Challenges
Treatment Resistance
One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.
Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.
Key Market Trends
Patient-Centered Care
Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.
Key Market Players
• Eli Lilly and Company
• Grunenthal GmBH
• Collegium Pharmaceutical, Inc.
• Lupin Ltd
• Daiichi Sankyo Inc.
• Azurity Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Endo International plc. (Par Pharmaceutical)
• Johnson & Johnson
Report Scope:
In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Diabetic Neuropathic Pain Market, By Neuropathy Type:
o Peripheral Neuropathy
o Autonomic Neuropathy
o Proximal Neuropathy
o Focal Neuropathy
• Diabetic Neuropathic Pain Market, By Drug Class:
o Antidepressants
o Anticonvulsants
o Analgesics
• Diabetic Neuropathic Pain Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Diabetic Neuropathic Pain Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.
Available Customizations:
Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Diabetic Neuropathic Pain Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy)
4.2.2. By Drug Class (Antidepressants, Anticonvulsants, Analgesics)
4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Neuropathy Type
4.3.2. By Drug Class
4.3.3. By Distribution Channel
4.3.4. By Region
5. Asia Pacific Diabetic Neuropathic Pain Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Neuropathy Type
5.2.2. By Drug Class
5.2.3. By Distribution Channel
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Diabetic Neuropathic Pain Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Neuropathy Type
5.3.1.2.2. By Drug Class
5.3.1.2.3. By Distribution Channel
5.3.2. India Diabetic Neuropathic Pain Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Neuropathy Type
5.3.2.2.2. By Drug Class
5.3.2.2.3. By Distribution Channel
5.3.3. Australia Diabetic Neuropathic Pain Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Neuropathy Type
5.3.3.2.2. By Drug Class
5.3.3.2.3. By Distribution Channel
5.3.4. Japan Diabetic Neuropathic Pain Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Neuropathy Type
5.3.4.2.2. By Drug Class
5.3.4.2.3. By Distribution Channel
5.3.5. South Korea Diabetic Neuropathic Pain Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Neuropathy Type
5.3.5.2.2. By Drug Class
5.3.5.2.3. By Distribution Channel
6. Europe Diabetic Neuropathic Pain Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Neuropathy Type
6.2.2. By Drug Class
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Diabetic Neuropathic Pain Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Neuropathy Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Distribution Channel
6.3.2. Germany Diabetic Neuropathic Pain Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Neuropathy Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Distribution Channel
6.3.3. Spain Diabetic Neuropathic Pain Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Neuropathy Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Distribution Channel
6.3.4. Italy Diabetic Neuropathic Pain Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Neuropathy Type
6.3.4.2.2. By Drug Class
6.3.4.2.3. By Distribution Channel
6.3.5. United Kingdom Diabetic Neuropathic Pain Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Neuropathy Type
6.3.5.2.2. By Drug Class
6.3.5.2.3. By Distribution Channel
7. North America Diabetic Neuropathic Pain Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Neuropathy Type
7.2.2. By Drug Class
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Diabetic Neuropathic Pain Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Neuropathy Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Distribution Channel
7.3.2. Mexico Diabetic Neuropathic Pain Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Neuropathy Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Distribution Channel
7.3.3. Canada Diabetic Neuropathic Pain Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Neuropathy Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Distribution Channel
8. South America Diabetic Neuropathic Pain Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Neuropathy Type
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Diabetic Neuropathic Pain Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Neuropathy Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Distribution Channel
8.3.2. Argentina Diabetic Neuropathic Pain Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Neuropathy Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Distribution Channel
8.3.3. Colombia Diabetic Neuropathic Pain Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Neuropathy Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Distribution Channel
9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Neuropathy Type
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Diabetic Neuropathic Pain Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Neuropathy Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Distribution Channel
9.3.2. Saudi Arabia Diabetic Neuropathic Pain Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Neuropathy Type
9.3.2.2.2. By Drug Class
9.3.2.2.3. By Distribution Channel
9.3.3. UAE Diabetic Neuropathic Pain Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Neuropathy Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Distribution Channel
9.3.4. Egypt Diabetic Neuropathic Pain Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Neuropathy Type
9.3.4.2.2. By Drug Class
9.3.4.2.3. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Diabetic Neuropathic Pain Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Eli Lilly and Company
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. SWOT Analysis
14.2. Grunenthal GmBH
14.3. Collegium Pharmaceutical, Inc.
14.4. Lupin Ltd
14.5. Daiichi Sankyo Inc.
14.6. Azurity Pharmaceuticals, Inc.
14.7. Novartis AG
14.8. Pfizer, Inc.
14.9. Endo International plc. (Par Pharmaceutical)
14.10.Johnson & Johnson
15. Strategic Recommendations
16. About Us & Disclaimer